주요 내용으로 건너 뛰기

Transform Your Early Drug Development with Population Pharmacokinetic Analysis

Are you maximizing the value of your clinical and non-clinical pharmacokinetic data? Traditional PK analysis methods might overlook critical insights. Population pharmacokinetic (PopPK) analysis can reveal relationships in your data to help drive better decision-making.

Leveraging PopPK techniques can enhance characterizing of the pharmacokinetics of drugs. Download the white paper to learn how!

Key benefits of early PopPK implementation:

  • Extract deeper insights from existing PK data without additional studies
  • Predict human exposure more accurately from non-clinical data
  • Identify crucial covariate relationships early in development
  • Support better clinical trial designs

Fill out this form to learn how PopPK analysis can transform your early drug development efforts!

Why choose Certara software?

Our Phoenix NLME software makes sophisticated PopPK analysis accessible and efficient, letting you focus on interpreting results rather than managing complex calculations. Certara’s integrated pharmacokinetic and pharmacodynamics analysis software can analyze data from non-clinical research through Phase 3 trials, all within a single, validated environment.

Powered by Translations.com GlobalLink Web Software